Literature DB >> 19296043

Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy.

Alexis Duez1, Eddy Cotte, Olivier Glehen, François Cotton, Naoual Bakrin.   

Abstract

BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an aggressive strategy to treat patients presenting peritoneal carcinomatosis from various origins. The aim of this study was to evaluate the correlation between the peritoneal cavity's capacity and the weight, the size and the body mass index (BMI) of patients to see if it would be relevant to adapt the pharmacology of HIPEC based on these factors.
MATERIALS AND METHODS: This study included 100 patients who had chest-abdominal-pelvic Computerised Tomography (CAP-CT) for various reasons. They were chosen randomly (53 males; 47 females; age range 19-96; mean 58 years). Weight and height of each of them were recorded with their identity on a model sheet given to nurses accustomed to work in clinical trials, before the CAP-CT. The BMI was then calculated from these two values. All the subjects were scanned with CT (Philips Brilliance 40, Cleveland, USA) and the volume of the peritoneal cavity, the liver and the spleen of each was measured with Centricity PACS LS software or Volume Viewer 2 (AW Suite 2.0 6.5.1 u) software.
RESULTS: The rates of correlation between the weight, the size, the BMI and the volume of the peritoneal cavity in which the volumes of the liver and the spleen were removed are 0.674, 0.317 and 0.576, respectively; and those of the weight, the size, the BMI and the volume of the peritoneal cavity without taking into account the volume occupied by the liver and spleen are 0.749, 0.348 and 0.644, respectively.
CONCLUSION: The peritoneal cavity's capacity is mainly correlated with weight and the interest to assess the volume of liver and spleen remains questionable in terms of results.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296043     DOI: 10.1007/s00276-009-0483-1

Source DB:  PubMed          Journal:  Surg Radiol Anat        ISSN: 0930-1038            Impact factor:   1.246


  14 in total

1.  The effects of heat and radiation on cancers implanted on the feet of mice.

Authors:  G CRILE
Journal:  Cancer Res       Date:  1963-03       Impact factor: 12.701

2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.

Authors:  J Esquivel; R Sticca; P Sugarbaker; E Levine; T D Yan; R Alexander; D Baratti; D Bartlett; R Barone; P Barrios; S Bieligk; P Bretcha-Boix; C K Chang; F Chu; Q Chu; S Daniel; E de Bree; M Deraco; L Dominguez-Parra; D Elias; R Flynn; J Foster; A Garofalo; F N Gilly; O Glehen; A Gomez-Portilla; L Gonzalez-Bayon; S Gonzalez-Moreno; M Goodman; V Gushchin; N Hanna; J Hartmann; L Harrison; R Hoefer; J Kane; D Kecmanovic; S Kelley; J Kuhn; J Lamont; J Lange; B Li; B Loggie; H Mahteme; G Mann; R Martin; R A Misih; B Moran; D Morris; L Onate-Ocana; N Petrelli; G Philippe; J Pingpank; A Pitroff; P Piso; M Quinones; L Riley; L Rutstein; S Saha; S Alrawi; A Sardi; S Schneebaum; P Shen; D Shibata; J Spellman; A Stojadinovic; J Stewart; J Torres-Melero; T Tuttle; V Verwaal; J Villar; N Wilkinson; R Younan; H Zeh; F Zoetmulder; G Sebbag
Journal:  Ann Surg Oncol       Date:  2006-10-28       Impact factor: 5.344

3.  High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.

Authors:  Philippe Esquis; David Consolo; Guy Magnin; Philippe Pointaire; Philippe Moretto; Maria Dolores Ynsa; Jean-Luc Beltramo; Carole Drogoul; Michel Simonet; Laurent Benoit; Patrick Rat; Bruno Chauffert
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Robert M Smeenk; Vic J Verwaal; Ninja Antonini; Frans A N Zoetmulder
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  [Spontaneous or induced history of the peritoneum and peritonitis].

Authors:  E Levy; R Parc; C Guilmet; J Loygue
Journal:  Ann Chir       Date:  1985-11

6.  Docetaxel and hyperthermia: factors that modify thermal enhancement.

Authors:  Faheez Mohamed; O Anthony Stuart; Olivier Glehen; Muneyasu Urano; Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2004-10-01       Impact factor: 3.454

Review 7.  Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.

Authors:  Olivier Glehen; Faheez Mohamed; François N Gilly
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

8.  In vivo peritoneal surface area measurement in rats by micro-computed tomography (microCT).

Authors:  Elodie Breton; Philippe Choquet; Laure Bergua; Mariette Barthelmebs; Börje Haraldsson; Jean-Jacques Helwig; André Constantinesco; Michel Fischbach
Journal:  Perit Dial Int       Date:  2008 Mar-Apr       Impact factor: 1.756

Review 9.  Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.

Authors:  P H Sugarbaker
Journal:  Int J Hyperthermia       Date:  2007-08       Impact factor: 3.914

10.  Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.

Authors:  D Elias; T Matsuhisa; L Sideris; G Liberale; L Drouard-Troalen; B Raynard; M Pocard; J M Puizillou; V Billard; P Bourget; M Ducreux
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

View more
  1 in total

1.  CT quantification of hemoperitoneum volume in abdominal haemorrhage: a new method.

Authors:  Damien Massalou; Marie Baqué-Juston; Pauline Foti; Pascal Staccini; Patrick Baqué
Journal:  Surg Radiol Anat       Date:  2012-12-21       Impact factor: 1.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.